Is Taking Hydroxyzine Bad for Your Heart?

Hydroxyzine carries a real but generally small risk to heart rhythm at standard doses, primarily through its ability to delay the electrical recovery of heart cells in a way that can, in rare cases, trigger a dangerous type of irregular heartbeat. For most people taking it as prescribed for allergies, itching, or anxiety, the cardiac risk is low. But the concern is not hypothetical: regulatory agencies in Europe and Canada have issued formal safety advisories about hydroxyzine and heart rhythm problems, and case reports of serious arrhythmias do exist. Whether that risk matters for you depends on dose, other medications, and a handful of personal health factors worth understanding.

What Hydroxyzine Actually Does to the Heart

Hydroxyzine is a first-generation antihistamine that has been around since the 1950s. It works by blocking histamine receptors, which is why it helps with allergic reactions and itching, and it also has sedating and anti-anxiety properties. But like a number of older medications, it doesn’t just target histamine receptors. It also interacts with ion channels in heart muscle cells, and that’s where the cardiac concern originates.

The specific issue is hydroxyzine’s effect on a potassium channel called hERG (sometimes written HERG). These channels are responsible for helping heart cells reset their electrical charge after each beat. When a drug blocks hERG channels, the heart’s electrical recovery takes longer. On an electrocardiogram (ECG), this shows up as a prolonged QT interval. A prolonged QT interval doesn’t cause problems by itself most of the time, but in certain circumstances it can set the stage for a fast, chaotic heart rhythm called torsade de pointes (TdP), which can cause fainting or, very rarely, sudden cardiac death.

Laboratory studies have confirmed that hydroxyzine blocks hERG channels in a dose-dependent way. One study found that hydroxyzine significantly increased the duration of the heart cell’s action potential at concentrations that are achievable with clinical dosing.¹ A separate investigation measured hydroxyzine’s potency against hERG channels and found that the concentration needed to block half the channel current was quite low, around 0.39 micromoles per liter at body temperature.²

There is a partial silver lining in the pharmacology, though. The same study found that hydroxyzine also blocks certain sodium and calcium channels in the heart. Blocking those channels has the opposite electrical effect, shortening the action potential rather than lengthening it. This partial counterbalancing may explain why clinically significant QT prolongation from hydroxyzine is relatively uncommon despite its potent hERG blockade in a test tube.² In other words, the drug’s real-world cardiac effect is milder than the hERG blockade alone would predict, because other ion channel effects partially cancel it out.

How Often Does Hydroxyzine Actually Cause Heart Problems?

Laboratory findings about ion channels are important for understanding the mechanism, but what matters most to someone filling a prescription is the real-world track record. Here the picture is reassuring for most people, though not entirely clean.

Torsade de pointes from hydroxyzine has been documented in case reports and literature reviews. A 2023 case report and accompanying review of the medical literature highlighted TdP as a recognized adverse effect of hydroxyzine, noting that while rare, it represents a serious potential outcome.³ These are isolated reports, not population-level epidemics, and they tend to cluster in patients who had additional risk factors like other QT-prolonging medications, electrolyte abnormalities, or pre-existing heart conditions.

One especially instructive case involved a patient who carried a genetic mutation in the hERG gene itself. The study found that hydroxyzine blocked both normal and mutant hERG channels, with the mutant channels being slightly more sensitive to the drug. The researchers concluded that the combination of the genetic vulnerability and hydroxyzine intake likely triggered syncope due to torsade de pointes.⁴ Most people don’t know whether they carry such a mutation, and many who do have never experienced symptoms, which makes the risk somewhat unpredictable at the individual level.

It’s worth putting this in context: many commonly used medications carry some degree of QT prolongation risk. In a study evaluating ECG monitoring practices for patients on psychotropic medications, hydroxyzine appeared among the most frequently co-prescribed drugs with a known or possible risk of TdP, alongside medications like ondansetron, quetiapine, and trazodone.⁵ Hydroxyzine is not uniquely dangerous in this regard. It belongs to a fairly large category of medications that clinicians should be aware of, especially when a patient is on multiple drugs from the same risk category.

Who Faces a Higher Risk

The cardiac risk from hydroxyzine is not evenly distributed. Certain factors meaningfully increase the chance that hERG channel blockade will translate into a clinically significant problem. Understanding these helps clarify whether the risk is relevant to you personally.

Existing long QT: People born with long QT syndrome or who have an already-prolonged QT interval from another cause are starting from a higher electrical baseline. Adding hydroxyzine on top of that can push the interval into a truly dangerous range. The case of the patient with a hERG gene mutation illustrates this well: the drug alone might not have caused trouble, but combined with a genetic predisposition, it did.⁴
Other QT-prolonging drugs: If you’re taking other medications that also block hERG channels or prolong the QT interval, the effects stack. Common culprits include certain antibiotics, antifungals, antipsychotics, and some antidepressants. Taking two or three of these together multiplies the risk considerably.
Low potassium or magnesium: Electrolyte imbalances make the heart more susceptible to rhythm disturbances. People taking diuretics, those with chronic kidney disease, or anyone with prolonged vomiting or diarrhea can end up with low levels of these minerals, which lower the threshold for TdP.
Advanced age: Older adults tend to have slower drug metabolism, which means hydroxyzine and its active metabolite stay in the body longer, effectively increasing the dose the heart sees. They are also more likely to have pre-existing heart conditions and to be on multiple medications.
High doses: The effect on hERG channels is dose-dependent. At standard prescribed doses for itching or anxiety (typically 25 to 50 mg), the risk is substantially lower than at higher doses or in overdose situations.
Liver impairment: Hydroxyzine is metabolized in the liver. If liver function is reduced, the drug clears more slowly, and blood levels can rise higher than expected at normal doses.

For a healthy adult under 65 taking hydroxyzine at a normal dose without other QT-prolonging medications and with normal electrolytes, the cardiac risk is genuinely small. The risk starts climbing when two or more of the factors above overlap.

What Regulatory Agencies Have Said

In 2015, the European Medicines Agency (EMA) issued a safety advisory specifically about hydroxyzine and the risk of QT prolongation. The advisory recommended dose restrictions, particularly for older adults, and advised against use in patients with known risk factors for arrhythmia. Health Canada issued a similar advisory. These actions reflected growing pharmacovigilance data, not a sudden discovery: the drug’s hERG-blocking activity had been known to researchers for some time, but regulatory bodies decided the signal warranted formal action.

A longitudinal study examined how prescribing behavior changed after these advisories. In the UK, hydroxyzine prescriptions dropped by about 21% in the twelve months following the advisory compared to what would have been expected based on pre-advisory trends.⁶ In British Columbia, Canada, however, the advisory had no measurable impact on prescribing rates. The same study found something revealing: the decrease in UK prescriptions was not concentrated among patients with risk factors for QT prolongation. In other words, doctors appeared to be prescribing hydroxyzine less overall, but they weren’t specifically targeting the reduction toward the patients most likely to have a problem.⁶ That’s a gap in practice: ideally, the patients who stop getting hydroxyzine first would be the ones at highest cardiac risk, not a broad, non-specific pullback.

The United States FDA has not issued a standalone safety alert about hydroxyzine and cardiac risk on the same scale as the EMA, but hydroxyzine’s drug labeling does include warnings about QT prolongation. Prescribing practices in the U.S. have been influenced by the EMA action and by increased general awareness among clinicians, though hydroxyzine remains widely used in emergency departments, psychiatric facilities, and primary care.

How Hydroxyzine Compares to Other Antihistamines

If you’re worried about the heart effects of hydroxyzine, you might wonder whether the problem extends to all antihistamines. It does not. The cardiac risk from hERG channel blockade is not a class effect shared by every drug that blocks histamine receptors.⁷

Two older antihistamines, terfenadine and astemizole, were actually pulled from the market in the late 1990s because of deaths linked to QT prolongation and torsade de pointes.⁷ Their removal was a watershed moment in drug safety and prompted much more rigorous cardiac screening for new antihistamines. The second-generation antihistamines available today, like loratadine and fexofenadine, were specifically evaluated for cardiac safety and have shown no clinically meaningful QT effects at recommended doses.

Interestingly, hydroxyzine’s main active metabolite is cetirizine (sold as Zyrtec and generic equivalents). When your body processes hydroxyzine, a significant portion is converted to cetirizine, which then does most of the allergy-fighting work. Cetirizine has a much better cardiac safety profile than its parent drug. If your primary reason for taking hydroxyzine is allergies or itching rather than anxiety, cetirizine offers similar antihistamine benefits without the same degree of hERG channel blockade. This makes it a reasonable conversation to have with your prescriber if you have cardiac risk factors. The trade-off is that cetirizine doesn’t have hydroxyzine’s anxiolytic properties, so it’s not a direct swap for everyone.

Why Hydroxyzine Is Still Prescribed Despite the Risk

Given the cardiac warnings, you might wonder why doctors haven’t simply stopped prescribing hydroxyzine. The answer is that for certain uses, it fills a niche that other medications don’t cover as cleanly.

For generalized anxiety disorder, hydroxyzine has been shown to be effective in controlled trials and is one of relatively few non-addictive options available for short-term or as-needed anxiety relief. A review of pharmacologic alternatives to standard treatments for generalized anxiety found that hydroxyzine was among the most effective options studied.⁸ Unlike benzodiazepines, it carries no risk of physical dependence, which makes it attractive for patients with a history of substance use disorders or for clinicians who want to avoid prescribing controlled substances. Unlike SSRIs and SNRIs, it works within hours rather than weeks, which makes it useful for situational anxiety.

For acute itching and urticaria, hydroxyzine remains a go-to in emergency departments partly because of its sedating properties, which help patients who are distressed, and partly because of its long track record. In perioperative settings, it’s used for its combined antihistamine, anti-nausea, and sedative effects. No single alternative covers all three.

The clinical calculus for most prescribers is that the cardiac risk at normal doses in patients without risk factors is small enough to justify the drug’s benefits. That judgment shifts, appropriately, when a patient has heart disease, is elderly, or is taking other QT-prolonging medications.

Practical Steps If You Take Hydroxyzine

If you’re currently taking hydroxyzine and feeling anxious about the cardiac risk (an ironic situation given that anxiety is one of the things it’s prescribed for), there are concrete steps that can help.

First, know your risk factors. If you have no history of heart rhythm problems, your electrolytes are normal, you’re under 65, and you’re not on other QT-prolonging drugs, the cardiac risk from a standard dose of hydroxyzine is very low. You don’t need to panic or stop taking the medication abruptly based on a general warning. Stopping suddenly isn’t dangerous with hydroxyzine (it doesn’t cause withdrawal), but doing so without a plan can leave the underlying condition untreated.

Second, review your full medication list with a pharmacist or prescriber. Drug interactions are the most modifiable risk factor. Sometimes a patient ends up on two or three QT-prolonging medications prescribed by different doctors who don’t know about each other’s prescriptions. A single medication review can catch these combinations.

Third, if you have any of the high-risk factors discussed earlier, ask your prescriber whether a baseline ECG makes sense. Some clinical guidelines recommend ECG monitoring for patients on QT-prolonging medications, though adherence to this recommendation in practice is inconsistent.⁵ An ECG can identify whether your QT interval is already on the longer side, which would make switching to a different medication prudent.

Fourth, stay within the prescribed dose. The temptation to take extra hydroxyzine when anxiety or itching spikes is understandable, but the cardiac effect is dose-dependent. Taking double or triple the prescribed amount meaningfully increases the risk, especially if other factors are in play.

Symptoms That Should Prompt Immediate Attention

Most people on hydroxyzine will never experience a cardiac event from the drug. But knowing the warning signs of a rhythm disturbance is reasonable, especially in the first few days after starting the medication or after a dose increase.

The symptoms of a prolonged QT interval or early torsade de pointes are not subtle once they start. Sudden fainting or near-fainting without an obvious cause (like standing up too quickly) is the most common presentation. Heart palpitations that feel unusually fast, irregular, or “fluttering” can also be a sign, though garden-variety anxiety palpitations are far more common and are not the same thing. Dizziness that comes on suddenly and doesn’t pass, especially if it’s accompanied by a feeling that your heart is racing or skipping, warrants a prompt call to your doctor or a trip to urgent care.

Seizures can also occur with severe QT prolongation and TdP, because the brain doesn’t get enough blood flow during the arrhythmia. This is a medical emergency and calls for 911 or its equivalent immediately.

To be clear, these symptoms are rare in people taking hydroxyzine at prescribed doses. But they are worth knowing about, especially if you have one or more risk factors. If you experience unexplained syncope while taking hydroxyzine, your medical team should consider an ECG and a review of whether the medication is the right fit for you going forward.